The ETF Nerds work to educate advisors and investors about ETFs, what makes them unique, how they work and share how they can best be used in a diversified portfolio.
Artificial Intelligence is an area of computer science that focuses the creation of intelligent machines that work and react like humans. See our independently curated list of ETFs to play this theme here.
Blockchain technology allows for a recorded incorruptible decentralized digital ledger of all kinds of transactions to be distributed on a network. See our independently curated list of ETFs to play this theme here.
ESG Investing is the consideration of environmental, social and governance factors alongside financial factors in the investment decision–making process. See our independently curated list of ETFs to play this theme here.
Marijuana is often referred to as weed, MJ, herb, cannabis and other slang terms. It’s the green or gray dried flowers of Cannabis sativa. See our independently curated list of ETFs to play this theme here.
This ETF is one of several options for achieving exposure to the pharma industry, a corner of the health care market that is capable of delivering big returns but that also comes with some unique risk factors. Given this investment objective, PPH is probably more useful for those looking to achieve tactical exposure to this specific corner of the market; the appeal to buy-and-holders will be limited since many of the components are included in more broad-based funds.
A couple aspects of PPH are noteworthy. First, though PPH is now structured as a true ETF, it used to be one of the HOLDRS products offered by Merrill Lynch. Some of the concentration that was characteristic of those products remains in PPH; the portfolio is relatively shallow and concentration in the top allocations is significant. Further, PPH includes only U.S. stocks, meaning that some of the biggest players in the pharmaceutical industry are excluded from the underlying portfolio.
PPH is a decent option for pharma exposure, but there are probably some better ETFs out there for tapping into this segment of the market. IHE offers better depth of holdings, while DRGS may be appealing to those looking to achieve truly global exposure.
Historical Trading Data
1 Month Avg. Volume64,645
3 Month Avg. Volume44,742
Alternative ETFs in the Health & Biotech Equities Category
5 Day Net Flows:
0
1 Month Net Flows:
9.94 M
3 Month Net Flows:
3.83 M
6 Month Net Flows:
31.27 M
1 Year Net Flows:
68.47 M
3 Year Net Flows:
-54.8 M
5 Year Net Flows:
-104.66 M
10 Year Net Flows:
-300.57 M
Realtime Rating
The adjacent table gives investors an individual Realtime Rating for PPH on several different metrics, including liquidity, expenses, performance, volatility, dividend, concentration of holdings in addition to an overall rating. The "A+ Metric Rated ETF" field, available to ETFdb Pro members, shows the ETF in the Health & Biotech Equities with the highest Metric Realtime Rating for each individual field. To view all of this data, sign up for a free 14-day trial for ETFdb Pro. To view information on how the ETFdb Realtime Ratings work, click here.
Fact sheets are issued by the ETF provider and framed by ETFdb.com. Information contained within the fact sheet is not guaranteed to be timely or accurate.
Copyright MSCI ESG Research LLC [2018]. All Rights Reserved. MSCI ESG Research LLC’s (“MSCI ESG”) Fund Metrics products (the “Information”) provide environmental, social and governance data with respect to underlying securities within more than 23,000 multi-asset class Mutual Funds and ETFs globally. MSCI ESG is a Registered Investment Adviser under the Investment Advisers Act of 1940. MSCI ESG materials have not been submitted, to nor received approval from, the US SEC or any other regulatory body. None of the information constitutes an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product or trading strategy, nor should it be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. None of the Information can be used to determine which securities to buy or sell or when to buy or sell them. The Information is provided “as is” and the user of the Information assumes the entire risk of any use it may make or permit to be made of the Information. All Information is provided solely for your internal use, and may not be reproduced or redisseminated in any form without express prior written permission from MSCI. Neither MSCI ESG nor any of its affiliates or any third party involved in or related to creating any Information makes any express or implied warranties, representations or guarantees, and in no event will MSCI ESG or any such affiliate or third party have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) relating to any Information. More information on MSCI ESG Fund Metrics, provided by MSCI ESG Research LLC, can be found at https://www.msci.com/esg-fund-metrics.
Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use, please see disclaimer.
Advertisement
Is Your Portfolio Positioned With Enough Global Exposure?
